Plus Products Inc. (CSE: PLUS) (OTC: PLPRF)

The QualityStocks Daily Newsletter would like to spotlight Plus Products Inc. (CSE: PLUS) (OTC: PLPRF).

Plus Products Inc. (CSE: PLUS) (OTCQB: PLPRF) (the “Company” or “PLUS”), one of California’s top edibles brand and manufacturer by market share according to BDS Analytics, today announced its expansion into the Nevada market, its first market outside of California. PLUS has entered into a definitive agreement to partner with TapRoot Holdings Inc. (“Taproot”), a vertically integrated cannabis company operating cultivation and manufacturing facilities in Las Vegas, Nevada. Also today, NetworkNewsWire released a report on the company detailing how Plus Products’ newest addition to its product family — Create sour blueberry low-calorie gummies —is infused with hybrid flower and contains 5.0mg of THC. Moreover, the gummies are gluten-free and made with kosher ingredients. Additionally, the company was featured in the 420 with CNW by CannabisNewsWire. Banking associations from all the 50 states across the U.S. have written a letter to the Senate Banking Committee to pass and advance the bipartisan bill before it seeking to protect financial institutions from federal penalties for doing business with licensed marijuana businesses. In their letter delivered on April 20, the state banking associations observed that forcing cannabis businesses to operate on a cash-only basis exposes the businesses, their employees and the public to serious safety risks.

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF) is a branded cannabis-infused products manufacturer of edibles created to support a healthy and active lifestyle. Headquartered in San Mateo, California, PLUS™ concentrates on producing edibles using extracts to ensure compliant, dosable and delicious products that provide a consistent cannabis experience.

First introduced to the market in 2015 to rave reviews, PLUS™ is now one of the top best-selling edible brands in California. PLUS™ operates through a wholly owned subsidiary, Carberry, and has four cannabis-infused gummy candy SKUs (in addition to limited edition SKUs), that are currently sold in over 200 licensed dispensaries and delivery services. All products under the PLUS™ brand are produced in the company’s 12,000-square-foot food-safe cannabis manufacturing facility in Adelanto, California.

PLUS Products shares are currently listed on the Canadian Securities Exchange. PLUS™ raised CAD$20 million through the offering, for which the lead underwriters were PI Financial and Canaccord Genuity. The company intends to use a portion of the IPO proceeds to fund rapid product capacity expansion, factory automation, working capital and new product development.

Operating in the largest adult-use recreational market in the U.S., PLUS Products holds a temporary manufacturing license in California and was one of the first brands to bring fully compliant products to the legal market. California legalized adult use recreational sales on Jan. 1, 2018, and industry analysts expect edible sales there will continue to amass enviable revenues. According to BDS Analytics, edibles made up 18 percent of marijuana retail sales in February 2018 across licensed retailers in California, with PLUS™ products ranking in the Top 10 of edible brands by retail dollar sales.

During the first half of 2018, PLUS Products generated US$2.45 million in sales, a marked improvement over 2017’s US$1.07 million in sales. The company’s established cannabis products are not only compliant with state laws, they are proving to be extremely popular with consumers. Among the PLUS™ product brands are:

• Blackberry & Lemon RESTORE, an infusion of carefully dosed cannabis with a 9:1 THC to CBD per gummy.
• Sour Watermelon UPLIFT, a low-calorie gummy crafted from carefully dosed cannabis with an infusion of 5mg THC per gummy.
• Pineapple & Coconut CBD RELIEF, a tropical flavor gummy made from pure cannabis-derived CBD that is low-calorie, gluten-free and made with kosher ingredients.
• Sour Blueberry CREATE, a low-calorie gummy infused with hybrid flower containing 5 mg THC.
• Limited Edition Rose & Vanilla, available at select locations during Winter 2018, these gummies are crafted with 60 mg THC/30 mg CBD per tin.
• Limited Edition RAINBOW SORBET gummies was created to celebrate Pride during Spring 2018 with a portion of each purchase donated to The Trevor Project, a confidential suicide hotline for LGBT youth.

“We are extremely proud of the products PLUS has brought to market,” remarked Jake Heimark, CEO and cofounder in a statement. “We’ve quickly grown into one of the leading edible brands in California. With the proceeds of this round, we will continue to further our mission: to make cannabis safe and approachable for all types of consumers.”

The PLUS™ team believes that everyone deserves access to consistent, dosable and delicious cannabis products and strives to make that happen. Producing the best infused products at scale requires thoughtful collaboration among experts in many fields. At PLUS™, our team is comprised of Chefs, Chemists, Food Manufacturing Experts, Engineers, Machinists, Visionaries, Creatives, Strategists and others.

Plus Products Inc. (PLPRF), closed the day's trading session at $3.531, off by 1.09%, on 97,568 volume with 166 trades. The average volume for the last 3 months is 76,455 and the stock's 52-week low/high is $2.81/$6.008.

Recent News

• PLUS Announces Expansion into the Nevada Market
• Plus Products Inc. (CSE: PLUS) (OTCQB: PLPRF) Developing Offerings for Sophisticated Cannabis Consumers
• 420 with CNW – 50 State Banking Associations Urge Congress to Act on Marijuana Banking

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Biotechnology company and drug delivery platform innovator Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) this morning announced that combining Lexaria's DehydraTECH(TM) delivery technology with generic nanotech techniques has been proven to deliver 1,137% more cannabidiol ("CBD") into animal brain tissue following oral ingestion than certain existing industry formulations. To view the full press release, visit: http://nnw.fm/EK01l.

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including nicotine and cannabinoids. To achieve higher absorption rates and fast onset, consumers traditionally defaulted to smoking. Lexaria provides a superior administration method by delivering these substances through a patented process within edible food products, thus eliminating all the harmful health consequences of smoking.

Lexaria’s technology is unique in that it takes advantage of GRAS (Generally Recognized As Safe) food ingredients processed with its patented DehydraTECHTM technology to improve taste, remove odor, and decrease the time to onset of bitter-tasting drugs. Lexaria is primarily a B2B enterprise and has existing cannabinoid licensing agreements with companies in Canada, the largest-market states in the United States, and internationally. Lexaria has entered into a R&D partnership with one of the largest cigarette companies in the world for oral forms of nicotine delivery. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within popular foods such as coffee, tea, and supplements. These brands include ViPova™ and TurboCBD™.

In 2015, Lexaria commissioned an independent third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company’s technological process and lipid formulation improve intestinal absorption as much as 500%. Lexaria has conducted multiple rounds of studies including in vivo and human clinical. In absorption studies conducted on rats, for example, Lexaria detected nicotine in the animal’s bloodstream just two minutes after it entered the stomach. In a randomized, double blinded human clinical study, cannabidiol (CBD) was measure in the human bloodstream at a 317% higher rate 30 minutes after swallowing a capsule processed with DehydraTECH than a non-enhanced capsule of equal strength.

Lexaria also has an R&D partnership with the Canadian government’s National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria’s unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D have helped support B2B relationships with Fortune 500 companies. Lexaria has four distinct subsidiaries that focus on different market sectors: Hemp/CBD; Pharmaceutical; Cannabis; and Nicotine.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong and growing intellectual property portfolio. As of the end of 2018, the company’s patent portfolio includes 53 patent applications filed and pending in more than 40 countries around the world; and 10 patents granted to date. Lexaria is expecting additional new patent awards both in the U.S. and internationally in 2019 and beyond. Some of its more recent areas of investigation have included human hormones and erectile dysfunction substances, among others.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology (royalty) to third-partners and has signed royalty deals with start-up companies as well as with a Fortune 100. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has contributed to several multi-hundred million-dollar valuations over the course of his career. He is supported by a growing team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed the day's trading session at $0.9744, up 9.48%, on 61,160 volume with 81 trades. The average volume for the last 3 months is 109,008 and the stock's 52-week low/high is $0.75/$2.43.

Recent News

• NetworkNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH(TM) Combined with Nanotech Delivers 1,137 Percent More CBD into Animal Brain Tissue
• Lexaria Bioscience Announces the Issuance of Options and Warrants
• NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) and Nuka to Expand Cannabis Product Operations for DehydraTECH Powered Edibles

Nabis Holdings (CSE: NAB) (OTC: INNPF) (FRA: 71P)

The QualityStocks Daily Newsletter would like to spotlight Nabis Holdings (OTC: INNPF).

Innovative Properties Inc. d/b/a Nabis Holdings (CSE: NAB; OTC: INNPF; FRA: 71P) (“Nabis Holdings” or the “Company”), a leading Canadian investment company, with specialty investments in assets across multiple divisions of the cannabis sector, is pleased to announce that further to its news release dated May 6, 2019, the effective date for the Company’s name change to “Nabis Holdings Inc.” (the “Name Change”) and continuance into the province of British Columbia (the “Continuation”) will be May 29, 2019.  The Company’s Canadian Securities Exchange (“CSE”) ticker symbol NAB will remain unchanged. 

Nabis Holdings (CSE: NAB) (OTC: INNPF) (FRA: 71P), dba Innovative Properties Inc., is a Canadian investment company pursuing interests in high-quality cash-flow assets in real property, securities, cryptocurrency and all branches of the cannabis sector. The company's focus on strategic revenue generation, EBITDA and growth is enshrined in its moto, "One team. One goal," and is reflected in its name: "Na bis," which is defined as, "repeat performance" or "encore."

Strategy

While the Nabis' targets span numerous industries, the company aims to establish an Anchor Investment Portfolio primarily through the acquisition of majority interests in high quality U.S. cannabis assets and brands that have achieved cash flow. The company will then employ a hands-on approach to assist the investee in implementing standards and consistency to enhance their operations.

Criteria for investment targets are as follows:

• Positive EBITDA, vertically integrated operators in limited license states with large addressable markets
• Emphasis on operations that add material EBITDA within 12 months with enhanced access to capital and Nabis' value add approach on operations and brand consistency
• Identifying proven operators with good expertise to add value to a consolidation strategy
• Focused on MSOs (Multi-state Operators) with strong brand traction
• Pharma grade cultivation, extraction, dispensaries and other addressable operations

Current Endeavors

Nabis has completed investments in five Michigan properties with Cannabis provisioning, processing and cultivation licenses. The Company has also entered into binding Letters of Intent ("LOI") to invest in vertically integrated assets in Michigan, Arizona and Washington State. The company's goal is to be invested in four to five additional states in the coming months.

Arizona – LOI to acquire full control of Organica Patient Group Inc. ("OPG") and RDF Management Group. OPG is a fully integrated medical marijuana business licensed under the provisions of the Arizona Medical Marijuana Act. Its assets include the Chino Valley MMJ Dispensary and fully established Patient Group, which since 2012 has operated as "Organica Patient Group" in Chino Valley. OPG also operates a 26,000-square-foot indoor cultivation and processing center along with a 56,600-square-foot greenhouse in Prescott Valley; has its own branded products and wholesale operations which includes distribution to more than 25% of the dispensaries in Arizona; and has exclusive manufacturing and licensing agreements with Fire Brand, Gas Extracts and Donuts Concentrate products distributed within Arizona.

Michigan – LOIs to invest in multiple strategically located properties that have or are eligible for municipal approvals for provisioning centers in Michigan. The company is currently evaluating 10 to 15 additional municipally approved locations in Michigan that would substantially increase the company's overall presence in the U.S. cannabis space.

Washington State – LOI to purchase assets from PDT Technologies LLC, including extraction and production equipment and rights to lease the current production facility in Port Townsend, Wash. The LOI includes licensing rights to produce Chong's Choice Brand CO2 Vape Cartridges, one of the leading and most recognizable brands in the cannabis space. Expansion plans include construction of a new ISO designed extraction clean room and GMP lab facility with new, highly specialized equipment with two extraction lines. The facility could produce up to 20,500 kg of cannabis concentrate on an annual basis.

Hivemind Refinery – LOI to invest in a 70% interest of Hivemind Refinery, an established line of CBD-based wellness products in the United States. The investment into Hivemind expands Nabis' investment portfolio to CBD edibles, water, drops, lotions, and other CBD wellness products across the spectrum. Nabis anticipates Hivemind will be a premium consumer CBD line to be distributed across the U.S. and Canada and will focus on products utilizing locally grown, premium CBD along with unique formulations and delivery systems.

Bloombox – binding term sheet with Momentum Ideas Co. to acquire certain assets used and marketed under the brand "Bloombox," a leading intelligent retail cannabis software platform that includes the Bloombox Software and data platform. The acquisition of Bloombox will create a dominating presence in the U.S. cannabis market, featuring an integrated ecosystem of modern, next-generation cannabis technology. Bloombox is one of the world's first standards-based cannabis software systems, enabling frictionless integration with nearly any business system or regulatory body.

Proven Management Team

CEO and Director Shay Shnet has over 20 years of experience in business and was most recently a founding partner and vice president of operations of MPX Bioceutical (CSE: MPX). While at MPX, Shnet focused on the North American cannabis space and helped build the company's portfolio of international cannabis assets. He is highly skilled in finding unique opportunities and has been directly involved with the development, branding, importing, consumer packaging and distribution of a wide variety of product lines.

President Mark Krytiuk is a very successful cannabis operator and was a founding partner of MPX. As the vice president of grow operations of MPX, he oversaw the production of medical marijuana and pharma-grade products across North America. He has been directly involved in overseeing the rapid expansion and buildout of nine facilities in three countries with budgets ranging up to $30 million. Krytiuk's experience includes consulting and working with customers to develop individual requirements for indoor and outdoor cannabis cultivation while working with federal regulators and licensing bodies to ensure compliance.

Nabis Holdings (OTC: INNPF), closed the day's trading session at $0.45311, up 2.28%, on 136,391 volume with 72 trades. The average volume for the last 3 months is 185,429 and the stock's 52-week low/high is $0.392/$0.791.

Recent News

• Nabis Changes Name to “Nabis Holdings Inc.” and Continuation Into BC
• 420 with CNW – New Jersey Legislators Approve Several Marijuana Bills
• Nabis Holdings to Participate in KCSA's Inaugural Congressional Cannabis Day Forum on May 21

QMC Quantum Minerals Corp. (OTC: QMCQF) (TSX-V: QMC) (FSE: 3LQ)

The QualityStocks Daily Newsletter would like to spotlight QMC Quantum Minerals Corp. (QMCQF).

QMC Quantum Minerals (TSX.V: QMC) (OTC: QMCQF) (FSE: 3LQ), a British Columbia-based company engaged in the business of acquisition, exploration and development of natural resource properties, is advancing toward potential commercial production of lithium at its Irgon Dike through the ongoing development of a NI 43-101-compliant resource estimate.

QMC Quantum Minerals Corp. (OTC: QMCQF) (TSX-V: QMC) (FSE: 3LQ) is a British Columbia based company engaged in the business of acquisition, exploration and development of natural resource properties. QMC’s focus is on creating shareholder value through strategic acquisition and development of high quality lithium, silver, gold, nickel, copper and zinc prospects.

QMC’s current properties are in the Canadian province of Manitoba, one of Canada’s most productive, centrally located mining regions. These resources include the Irgon Lithium Mine project and two Volcanic Massive Sulphide (“VMS”) properties – the Rocky Lake and Rocky-Namew known collectively as the Namew Lake District Project – which contain base metal-rich mineral deposits. Excellent access and well-developed mining infrastructure to the company’s wholly-owned Irgon Lithium Mine Project offers significant value and ramps up the near-term production schedule, putting QMC in a position to take advantage of rising lithium prices.

The region’s historic resource estimate of lithium is well documented in a 1956 Assessment Report developed by a previous owner, Lithium Corporation of Canada Ltd. The project’s historical resource estimate of 1.2 million tons grading 1.51% lithium-oxide over a strike length of 365 meters and to a depth of 213 meters is being updated by QMC through a detailed channel sampling and subsequent drill program.

North Face Software Ltd. recently created an interactive 3-D model of the Irgon Dike utilizing all historical data derived from past drilling and underground work. The 3-D model clearly demonstrates that exploration and underground development has only taken place on the central portion of the dike, leaving significant potential to quickly increase tonnage.

The company’s latest assay results, obtained from 144 channel samples at QMC’s Irgon Lithium Mine Project, provided encouraging and positive results that compare favorably with the historic assays. QMC has received a drill permit from the Sustainable Development Office of the Manitoba government and is in the process of requesting and assessing bids from drilling contractors. The company plans to begin a 2,000-meter drill program to confirm the historic lithium oxide assay results documented in the historic 1953-54 drill program.

QMC’s experienced leadership team includes specialists in mineral exploration, geology, engineering, new business development, marketing and investor relations. The company’s team of qualified advisors includes consultant Bruce E. Goad, P.Geo., who has 40 years of experience in mineral exploration in Canada, Argentina, Asia and Africa. As a Qualified Person, Goad has worked on numerous deposit styles including rare element pegmatites, porphyry, banded iron formation (BIF) gold deposits, skarn, greisens,  and VMS. He has a wide and varied skill set which includes precious, base, industrial and rare metal projects with a sharp focus on gold exploration. Goad is the author of several scholarly publications on pegmatite granites of the southeastern Manitoba region.

The market for lithium has surged over the past three years with prices per metric ton tripling. The world’s rising demand for portable power can easily been seen in the electric vehicle and mobile device industries – both of which use lithium-based, renewable batteries as a power resource. QMC’s high potential prospects and experienced management team, both in geology and corporate finance, put QMC and its shareholders in an excellent position to take advantage of the lithium, precious and base metals markets.

QMC Quantum Minerals Corp. (QMCQF), closed the day's trading session at $0.158875, up 1.39%, on 23,000 volume with 11 trades. The average volume for the last 3 months is 53,378 and the stock's 52-week low/high is $0.1155/$0.4607.

Recent News

• NetworkNewsBreaks – QMC Quantum Minerals Corp. (TSX.V: QMC) (OTC: QMCQF) (FSE: 3LQ) Evaluating Further Pegmatite Dikes at Irgon Project
• QMC Reports 2.97% Li2O Over 1.22 Metres at Central Dike
• QMC Confirms Significant Spodumene Mineralization in Historical Drill Core

Sugarmade, Inc. (SGMD)

The QualityStocks Daily Newsletter would like to spotlight Sugarmade, Inc. (SGMD).

Growing demand for CBD is increasing pressure on companies that provide key cultivation equipment and industry supplies. As part of its commitment to build a large and well-supplied sales channel, hydroponic supplier Sugarmade Inc. (OTCQB: SGMD) (SGMD Profile) is in the process of making acquisition of companies that supply the hemp industry.

Sugarmade, Inc. (SGMD), one of the largest publicly traded hydroponics supply companies moving into the industrial hemp space, is a product and brand marketing company investing in products and brands with disruptive potential. Sugarmade’s brands include: ZenHydro.com; CarryOutSupplies.com; and BudLife. Headquartered in Monrovia, California, a city within Los Angeles county, Sugarmade has various business operations in diverse marketplaces including packaging and paper goods for various industries, agricultural supplies.

Sugarmade has expanded into the European hydroponics supply market with a growing base of orders taken through Amazon UK. Over the past few financial quarters, Sugarmade has seen revenue growth patterns expand geographically. As recently as mid-2017, the majority of hydroponic-related revenue growth was seen from California and other West Coast marketplaces, however growth is becoming more geographically dispersed among U.S. states where legalization has eased restriction. This movement into the United Kingdom further expands the base of geographic growth areas for Sugarmade.

Sugarmade recently launched a new corporate initiative in the booming industrial hemp and CBD, committing up to $1 million in capital over the next 12 months to invest in Hempistry, Inc., a privately held Nevada corporation. Hempistry has begun planting an ultra-high cannabidiol (CBD) industrial hemp strain on a land option it holds on 23,000 acres of prime Kentucky farmland. The strain of industrial hemp being grown by Hempistry is ultra-rich in CBD but contains less than 0.3 percent of THC, the psychoactive ingredient found in cannabis. The U.S. hemp industry is expected to produce well over $1 billion in revenues in 2018, with a compound annual growth rate of 14 percent through 2022, according to the Hemp Business Journal.

Demand for industrial hemp and products derived from hemp is soaring, with no let-up in sight, which the company sees as a “tremendous opportunity to become a supplier to this fast-growing sector,” said Chairman and CEO Jimmy Chan, who is also an advisor and minority shareholder of Hempistry.

Sugarmade’s investment into the market for high-CBD hemp is expected to be highly accretive for common shareholders in two ways. First, Sugarmade’s investment will be in the form of common shares in Hempistry allowing Sugarmade common shareholders to possibly benefit from any future initial public offering of Hempistry. Second, Sugarmade is expected to sign a supply agreement with Hempistry for cultivation supplies, which would be additive to corporate revenues.

Sugarmade has also completed a master market agreement with industry leader BizRight Hydroponics, Inc., a leading marketer and manufacturer of cannabis and hydroponic growth supplies, which offers a range of hydroponics-related products including: HPS grow lights, electronic ballasts, HPS bulbs, nutrient mixes, environmental control products, pH measurement and calibration solutions and storage products. BizRight operates the ZenHydro.com website and other e-commerce properties and sells various products to distributors and retailers. BizRight is expected to produce in excess of $30 million in revenues during 2017, with substantial growth expected for 2018.

Sugarmade division CarryOutSupplies.com, the leader in paper and plastic take-out supplies, serves nationwide customers by offering a wide array of high quality products that are cost-efficient, custom-made and delivered on time. This business unit currently serves 2,000 quick service restaurants, garnering from 30-40 percent of the market share. Sugarmade plans to expand operations via the addition of market share and the introduction of new product offerings.

Management

CEO Jimmy Chan is an experienced business executive instrumental in growing multiple business operations with a strong expertise in international trade and banking, and international manufacturing and importation. He is also the founder of CarryOutSupplies.com, a company that revolutionized the custom-printed paper supplies subsector of the quick service restaurant industry, which merged with Sugarmade in 2014.

Arman Tabatabaei serves as operations consultant, providing high-level, day-to-day strategic guidance and tactical operational supervision for all aspects of the corporation’s business. He is an expert at data collection and analysis relative to resource management, risk forecasting and profit and loss management.

Sugarmade specializes in growing and acquiring innovative brands to maximize value for company employees, shareholders and other stakeholders. Sugarmade believes its future is very bright as the company expands operations within the cultivation sector and rapidly increases its revenue base. 6

Sugarmade, Inc. (SGMD), closed the day's trading session at $0.0318, up 4.61%, on 2,613,594 volume with 260 trades. The average volume for the last 3 months is 1,319,332 and the stock's 52-week low/high is $0.028/$0.1975.

Recent News

• CBD Surge Puts Pressure on Cultivation Supplies
• Sugarmade Inc.'s (SGMD) Artificial Intelligence Development to Enable Better Hemp Cultivation, Other Agricultural Monitoring
• Sugarmade Inc. Featured in CannabisNewsAudio Broadcast on Alarming Supply Shortage in CBD Industry

Geyser Brands Inc. (TSX.V: GYSR)

The QualityStocks Daily Newsletter would like to spotlight Geyser Brands Inc. (TSX.V: GYSR).

Geyser Brands Inc. (TSXV:GYSR) ("Geyser Brands" or the "Company") is pleased to announce that, further to the Company's news release dated February 11, 2019, the Company has entered into a definitive agreement (the "Agreement") in respect of the previously announced acquisition of Solace Management Group Inc. ("Solace"), a private corporation existing under the laws of British Columbia (the "Proposed Transaction").

Geyser Brands Inc. (TSX.V: GYSR) is a consumer healthcare company that builds and markets some of the world's most loved cannabis products and brands in the nutraceutical, cosmetics, food and beverage and pet sectors. Using its proprietary nanotechnology formulation, the company delivers creams, beverages, baked goods and tincture formulations with superior bioavailability and water solubility.

NanoFusion Technology

The efficacy of most hemp?products is restricted as the insoluble nature of the molecules prevents most of the product from permeating the skin or entering the body system. Geyser Brands solves this insolubility problem with an advanced delivery system that quickly and efficiently transports therapeutic agents directly to the bloodstream for maximum absorbency.

Made with all-natural materials, NanoFusion technology offers an array of advantages: enhances penetration for deeper skin penetration; improves the transport of active ingredients for site-specific targeting; delivers active ingredients across cell membranes for release within the cell; provides longer shelf-life and stability of molecules.

Operations

Geyser Brands operates a 7,000-square-foot facility in Port Coquitlam, British Columbia, where its initial cannabis cultivation generated the first revenues out of the company's cultivation license granted in October 2018. Geyser Brands is approved as a licensed producer in compliance with Health Canada standards, which allows the company to pursue its processing and sales license. Obtaining this license will enable the company to extend its products and brands into the regulated Canadian cannabis market and directly to the consumer medical market.

Geyser Brands's integrated production chain and formulation lab develops innovative products using high-quality hemp and CBD for healthy lifestyle brands while its R&D lab produces product formulations designed to enhance bio-availability of hemp and CBD and shelf stability while maintaining all-natural ingredients and ensuring premium quality.

Geyser Brands will continue to seek opportunities to invest into the research and development of unique high-quality proprietary strains and technologies that target specific health-related conditions such as pain and inflammation reduction, insomnia, digestive issues and other commonly known ailments.

Growing Portfolio

Among the brand formulations in Geyser Brand's portfolio are:

• Apothecary all-natural Hemp Terpene Pain Cream with optimal skin permeation
• Prohibition Cold Brew Mocha designed with water soluble hemp molecules
• Apothecary health products created to deliver fast-acting and high bioavailability in a spray formulation
• Baked hemp infused pet products, designed to alleviate anxiety and pain, created with NanoFusion for dosage control

Management Team

Since 2014, Geyser Brands' CEO and Co-Founder Andreas Thatcher has been a principal at Rhizome Group, an entertainment company focused on building media IP through creative and market development. He previously was a founding partner at Rhizome Capital LLC, a U.S.-based media?investment?company specializing in marketing and distribution financing, and worked in the Investment Banking industry in?London and Toronto. Thatcher holds a master's degree in economics.

CFO Barry McKnight obtained his bachelor's degree from the University of British Columbia and is a Chartered Professional Accountant and?Certified Management Accountant registered in British Columbia. McKnight has over 20 years of experience as the principal of Barry D. McKnight Inc. He formerly was also a director of Indigo Sky Capital Corp. and has been the CFO and a director of the Company since 2016 and Corporate?Secretary of the Company since 2017.

Geyser Brands's Co-Founder Brad Kersch brings a strong business background with over 20 years of experience in?successful startups and working?with Fortune 500 companies. He spent his early years in the advertising and?marketing field and went on to form Hyperware, a clothing?company that sold branded clothing to retailers across Canada?before selling to clothing giant Ocean Pacific (OP). Kersch?became the president of Shoreline Studios, Canada's largest and?oldest?studio for film and TV. In 2014 he started Solace Management Group, a hemp product company focused on pet, cosmeceutical, and nutraceutical markets. As of February 2019, Geyser Brands signed a non-binding LOI to acquire Solace Management. Upon completing the proposed Solace acquisition, Geyser Brands intends to launch into the execution phase of its plan — to take its brands global through retail and digital direct-to-consumer experiences, launching its hemp-infused cannabis brands and products in the U.S., European Union, and Asia, and its CBD-infused line of products in jurisdictions where the therapeutic ingredient is legal.

Kuldip Gill, head of Geyser Brands' R&D program, has more than 35 years of experience in the cannabis industry. Gill built the largest manufacturing facility?in the lower mainland in Surrey, British Columbia, complete with R&D, analytical and quality control labs approved by both the FDA and Health Canada. He has to date created over 3,500 formulas, most notably Lakota pain relief gel. Gill's experience and proven track record is evident in the strongly marketable formulations he has developed and sold worldwide.

Geyser Brands Inc. (TSX.V: GYSR), closed the day's trading session at $0.73, even for the day, on 15 volume with 1 trade. The average volume for the last 3 months is 8,376 and the stock's 52-week low/high is $0.61/$0.85.

Recent News

• Geyser Brands Inc. Announces Signing Of Definitive Agreement To Acquire Brands
• NetworkNewsBreaks – Geyser Brands Inc. (TSX.V: GYSR) and Brandeavour to Develop Compelling Approach to Brand Growth, Development
• Geyser Brands Inc. (TSX.V: GYSR) Records Robust Harvest, Prepares for Industry Expansion

Redfund Capital Corp. (CSE: LOAN) (OTCQB: PNNRF) (FF: O3X4)

The QualityStocks Daily Newsletter would like to spotlight Redfund Capital Corp. (PNNRF).

Redfund Capital Corp. (CSE: LOAN) (OTCQB: PNNRF) (Frankfurt: O3X4) was featured today in the 420 with CNW by CannabisNewsWire. Banking associations from all the 50 states across the U.S. have written a letter to the Senate Banking Committee to pass and advance the bipartisan bill before it seeking to protect financial institutions from federal penalties for doing business with licensed marijuana businesses.

Redfund Capital Corp. (CSE: LOAN) (OTCQB: PNNRF) (FF: O3X4) is a merchant bank focused on providing debt and equity funding in the mid to late stages of a target company’s development and for technologies that are developed and validated by revenues. Redfund’s current focus is on medical cannabis, hemp and cannabidiol (CBD) related and healthcare-related companies.

As the first medical cannabis incubator and accelerator financing medical cannabis, CBD and hemp companies through a debt facility, Redfund is effectively bridging finance gaps and helping revenue-producing medical cannabis-related companies grow and build their valuations without prematurely diluting their equity.

The central components of the company’s business strategy are:

• Establishing the foundation of a loan portfolio that generates revenues through monthly interest income from loans to cover all general and administrative expenses related to day-to-day operations.
• Growing shareholder value by converting all or part of loans and warrants into equity in portfolio clients as clients build their valuations by entering the public markets or becoming the high-priced targets of larger entities.

Redfund was designed by bankers and entrepreneurs possessing years of experience in business, consulting, capital markets, corporate finance and healthcare services. The company is actively looking beyond borders and creating global companies that have strong fundamentals and are ready to expand.

Redfund’s investments are deployed to companies that have demonstrated success in their business but need a capital bridge in order to expand. Redfund’s team of professionals vet every project and analyzes each prospective client’s financials and business plans. Once a project is approved, Redfund’s legal team carefully scrutinizes the collateral used to securitize the individual loans.

The strategy employed by Redfund includes:

• Diversifying investments in Canada and other countries
• Building an international footprint with established national leaders
• Funding new drug delivery systems and helping nutraceuticals become mainstream drugs
• Introducing companies to Canada as a viable option for public listings
• Becoming a premier go-to lender for established companies

The company’s revenue sources include:

• Interest-bearing debt instruments with asset-backed collateral to securitize loans
• Equity kicker of warrants coverage on original loan
• Conversion ability of loan in its entirety
• Advisory fees from contracts for consulting on growth strategies
• Right of first refusal on future financing in each company funded

Redfund Capital Corp. (OTCQB: PNNRF), closed the day's trading session at $0.09119, even for the day, on 999 volume. The average volume for the last 3 months is 538 and the stock's 52-week low/high is $0.09/$0.505.

Recent News

• 420 with CNW – 50 State Banking Associations Urge Congress to Act on Marijuana Banking
• NetworkNewsBreaks – Redfund Capital Corp. (CSE: LOAN) (OTCQB: PNNRF) (Frankfurt: O3X4) Increases Exposure through Recent Uplisting
• 420 with CNW – Medical Cannabis Home Delivery Service Begins in Michigan

INmune Bio Inc. (NASDAQ: INMB)

The QualityStocks Daily Newsletter would like to spotlight INmune Bio Inc. (NASDAQ: INMB).

INmune Bio, Inc. (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced today that David Moss, the Company’s co-founder and CFO, will present at the 9th Annual LD Micro Invitational. The event is being held at the Luxe Sunset Boulevard Hotel in Bel-Air, California, on June 4-5, 2019.

INmune Bio Inc. (NASDAQ: INMB) is a diversified clinical-stage immunology company developing novel therapies that target distinct parts of a patient's innate immune system to fight disease. Drug candidates INKmune™ and INB03 may be used to treat cancer while XPro1595 targets neuroinflammation as a cause of Alzheimer's disease. INmune Bio's product platforms utilize a precision therapy approach to promote the body's innate immune response to treat unsolved problems in medicine.

INmune Bio is the first biotechnology company to close an initial public offering (IPO) in 2019 and commence trading on The Nasdaq Capital Market. The company also received a "Part the Cloud" award from the Alzheimer's Association in 2018 which included a $1 million grant to advance INmune Bio's XPro1595 drug candidate.

INmune Bio's product pipeline targets three segments of concern:

• Alzheimer's disease/dementia claims 5.5 million patients in the United States. INmune Bio views Alzheimer's as an immunologic disease which changes the drug discovery process, changes the way clinical trials are designed, and may provide hope for patients and caregivers.
• Cancer residual disease which is expected to generate more than 1.7 million new cases yearly with an estimated 609,640 fatalities. INMB believe that converting resting Natural Killer ("NK") cells to primed NK cells, which kill cancerous cells on contact, is an important therapeutic strategy to help clear residual disease.
• Resistance to immunotherapy. By preventing the proliferation and function of cells that resist immunotherapy, patients should have a stronger immune response to cancer cells and may respond better to other cancer treatments including immunotherapy and live longer.

INmune Bio Drug Candidates and Clinical Programs

INKmune is a biologic delivery system that primes a patient's resting NK cells to kill cancer. INKmune targets residual disease for patients that have completed initial cancer therapy (surgery, radiation and/or chemotherapy) and have a low burden of disease with a high risk of relapse.

In late 2019, INKmune will start enrolling patients in a phase I/II trial for women with relapsed refractory ovarian cancer. In many patients, cancer relapse after seemingly effective cancer therapy is due to a failure of the patients own NK cells to eliminate minimal residual disease ("MRD").

Using a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance NK cells' ability to eliminate residual disease.

INB03 is a checkpoint inhibitor that targets myeloid derived suppressor cells ("MDSC") which can produce an immunosuppressive shield that prevents a patient's own immune system from attacking the cancer. INmune Bio is currently completing a monotherapy INB03 phase I trial in patients with advanced solid tumors. The INB03 program will transition into a combination therapy clinical program in the summer of 2019 to prepare for a phase II trial in patients resistant to checkpoint inhibitors due to increased MDSC.

Treatment with INB03 should eliminate MDSC in the tumor microenvironment to allow checkpoint inhibitors to be therapeutically effective.

XPro1595 targets the microglial immune cells of the brain that are activated in many Alzheimer's disease patients. These microglial cells are a cause of neuroinflammation that can kill nerve cells and promote synaptic dysfunction – the cause of dementia in Alzheimer's.

The three-month, phase I trial is expected to enroll 18 patients in summer of 2019. It is designed to measure traditional and novel biomarkers of inflammation in patients with mild to moderate Alzheimer's disease who have neuroinflammation. The trial is supported by a $1 million "Part the Cloud" grant from the Alzheimer's Association. Inflammation, especially chronic inflammation, is being recognized as an important part of the pathology of many diseases including cancer and Alzheimer's disease.

Management

Dr. RJ Tesi, M.D., INmune Bio co-founder, CEO and acting chief medical officer, has been a licensed physician since 1982 and a Fellow of the American College of Surgery since 1991. He received his medical degree from Washington University School of Medicine in 1982 and has served many roles in several development-stage biotech companies focused on treatment of neurodegenerative diseases, hematologic malignancies, and other inflammatory diseases.

CFO David J. Moss co-founder, has been with the company since its formation in September 2015. He holds an MBA from Rice University and a bachelor's degree in economics from the University of California, San Diego. Moss has founded, funded and taken public various companies in a variety of industries since 1995.

Mark Lowdell, Ph.D. co-founder, has served as the chief scientific officer and chief manufacturing officer at INmune Bio since the company's formation. He is a professor of cell and tissue therapy at University College London where he has led a translational immunotherapy group since 1994. He has also been a director of cellular therapy at the Royal Free London NHS Foundation Trust. He received his Ph.D. in clinical immunology from London Hospital Medical College, University of London in 1992 and is a qualified immunopathologist.

Christopher J. Barnum is director of neuroscience at INmune Bio. Barnum is a neuroimmunologist with broad expertise across neurodegenerative and psychiatric diseases holding multiple positions in academic and industry. His focus has been on translating inflammatory therapies into clinical treatments for neurologic diseases using a biomarker-directed approach. Barnum's research has been supported by the NIH, the Michael J. Fox Foundation, and the Alzheimer's Association. He received his Ph.D. in neuroscience from Binghamton University.

INmune Bio Inc. (OTC: INMB), closed the day's trading session at $10.59, off by 1.95%, on 8,434 volume with 76 trades. The average volume for the last 3 months is 18,106 and the stock's 52-week low/high is $7.00/$11.50.

Recent News

• INmune Bio to Present at the 9th Annual LD Micro Invitational on June 5th
• INmune Bio Announces Common Stock Purchase Agreement for up to $20.0 Million with Lincoln Park Capital
• NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Posts Q1 2019 Financial Results, Issues Shareholder Update

TransCanna Holdings Inc. (CSE: TCAN)

The QualityStocks Daily Newsletter would like to spotlight TransCanna Holdings Inc. (CSE: TCAN).

TransCanna Holdings (CSE: TCAN) (FSE: TH8) this morning announced that SolDaze, a company TransCanna recently entered into a non-binding Letter of Intent (“LOI”) with to acquire its business and assets, has started receiving pre-orders for its new Spicy Mango line of cannabis-infused mango snacks. To view the full press release, visit: http://nnw.fm/quB9i.

TransCanna Holdings Inc. (CSE: TCAN) through its subsidiaries specializes in assisting clients who are cannabis farmers and manufacturers get recognized by end consumers who in turn purchase their products. TransCanna offers or will be offering services to support almost every aspect of the cannabis-related eco-system; from branding and design, to transportation and distribution, to marketing and sales.

California’s legalized adult-use recreational marijuana market opened for business January 1, 2018. The state’s Bureau of Cannabis Control is responsible for regulating all commercial activities in the state including cultivation, distribution and transportation. Moving cannabis products in the California marketplace is extremely challenging due to municipal and state laws and regulations, which can differ among cities and counties. Since cannabis remains illegal under federal law, Department of Transportation regulated companies are barred from participating in the market, which means companies looking to excel in the sector must hold a state-issued distributor license from the Bureau of Cannabis Control.

TransCanna has already entered into an Intellectual Property Rights and Royalty Agreement for the Track & Trace software platform required by the state of California. TCM Distribution, the operating company managed by TransCanna, has received a transportation and distribution permit from the city of Adelanto and a temporary transportation and distribution permit from the state of California. TransCanna has also executed a land lease to build a 10,000-square-foot transportation and distribution facility in Adelanto.

TransCanna is strategically creating a distribution network throughout California that places its facilities no further than a three-hour drive from most any client. The company is in the process of leasing or purchasing properly licensed and permitted warehouses strategically located throughout California along with new secure trucks, sprinter vans and/or armored vehicles.

TransCanna plans to create its own portfolio of branded products for the cannabis and hemp sectors. The company’s management team intends to translate the skills, knowledge and experience gained from a combined 60 years of branding and marketing experience in the music, professional sports and alcohol industries into TransCanna and the cannabis industry.

As part of the “TransCanna Way,” the company intends to manage most aspects of the supply chain from upper end procurement, branding, transportation and distribution, to marketing and sales.

Leading TransCanna as its CEO and chairman is James Pakulis, who has three decades of experience working with public and private entrepreneurial companies in a variety of emerging and high-growth sectors. He is formerly the president and a director of Lifestyle Delivery Systems Inc. (CSE: LDS) (OTCQB: LDSYF), a vertically integrated cannabis-related entity operating in California. Pakulis was chairman and CEO of General Cannabis Inc. which from 2010 to 2012 owned WeedMaps. Pakulis oversaw the company’s growth from zero to over $16 million in annual revenue in less than 24 months.

The company’s strategic advisors include individuals with extensive experience in branding, marketing, sales, distribution, production and supply chain management.

For additional information, call: (604) 609-6199

TransCanna Holdings Inc. (CSE: TCAN), closed the day's trading session at $5.85, off by 5.80%, on 51,330 volume with 78 trades. The average volume for the last 3 months is 163,240 and the stock's 52-week low/high is $0.77/$7.79.

Recent News

• NetworkNewsBreaks – TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) Acquisition Target SolDaze Begins Taking Pre-Orders for Spicy Mango Line
• NetworkNewsBreaks – TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) Hires Soldaze, Inc. President and Co-Founder to Lead its Branding Division
• NetworkNewsBreaks – TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) Executes LOI to Acquire Premier Indoor Cultivator Business and Assets

Canopy Rivers Inc. (TSX.V: RIV) (OTC: CNPOF)

The QualityStocks Daily Newsletter would like to spotlight Canopy Rivers Inc. (RIV) (CNPOF).

Les Serres Vert Cannabis Inc. ("Vert Mirabel"), a subsidiary of Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) ("Canopy Growth") and a portfolio company of Canopy Rivers Inc. (TSXV: RIV) (OTC: CNPOF) ("Canopy Rivers") has received its final cultivation license from Health Canada. Also today, the company was announced that it would be hosting its analyst and investor day from 1:00 p.m. to 5:00 p.m. ET, May 28. The event was webcast live and all interested parties were invited to join. The webcast is available on Canopy Rivers' website at www.canopyrivers.com/investors/events. Additionally, the company was highlighted in a publication from Financialnewsmedia.com, examining how it’s become tough to ignore the cannabis story.

Canopy Rivers Inc. (TSX.V: RIV) (OTC: CNPOF) is the venture capital investment platform of Canopy Growth Corporation (TSX:WEED, NYSE:CGC).

Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers collaborates with Canopy Growth to identify strategic counterparties seeking financial and/or operating support. Headquartered in Toronto, Canada, Canopy Rivers has developed an ecosystem of complementary cannabis operating companies operating throughout the cannabis value chain.

Canopy Rivers, in collaboration with Canopy Growth, has established a diverse portfolio of cannabis industry investments that includes domestic and international companies, licensed producers, late-stage licensed producer applicants, pharmaceutical formulators, brand developers and distributors, retail networks, and technology and media platforms. Investments are customized for each counterparty and include a balanced mix of equity, debt, royalty and profit-sharing agreements.

Canopy Rivers’ expanding portfolio includes:

• Agripharm Corp. (private) is an ACMPR licensed producer, acquired by Canopy Growth in January 2017. In November 2017 Agripharm completed a joint venture with globally recognized partners Green House Seeds and Organa Brands. Canopy Growth has sublicensed proprietary technology, trademarks, genetics, know-how and other intellectual property from Agripharm to distribute the suite of Green House and Organa Brands products across the country, when permissible.
• CanapaR Corp. (private) owns 80% of CanapaR Italy, a Sicily-based company focused on developing and commercializing Italy’s local hemp cultivation industry through its partnership with the renowned Department of Agriculture at the University of Catania and its rapidly building extraction capabilities for the production of organic CBD oil. CanapaR Italy’s outsource farming model with local Sicilian farmers and its university partnership will provide it with a low-cost source of organic CBD oil, which is increasingly used as an input into new commercial products in the growing health and wellness industries.
• Civilized Worldwide Inc. (private), is a media and lifestyle brand with offices in New Brunswick and California that embraces and highlights modern cannabis culture. Civilized aims to engage the millions of productive, motivated people who choose to enjoy cannabis responsibly as part of their lifestyle. Reaching 2+ million unique visitors per month, North America-wide, Civilized produces engaging content for and about people who enjoy cannabis responsibly.
• James E. Wagner Cultivation Ltd. (TSXV:JWCA) was founded in 2007 by third generation agricultural and cannabis cultivators. JWC is the first entirely aeroponic producer of cannabis in Canada, and its patent-pending aeroponic production technology, called GrowthStormTM, allows for perpetual harvesting and improved yields. The company was issued a license to cultivate from Health Canada in January 2017 and a subsequent sales license in March 2018.
• LiveWell Foods Canada Inc. (TSXV:LVWL) was established in 1993 as a nutritional lifestyle company, and operates in the production of fresh produce and food technology. The company’s O-Hemp division distributes bulk and retail hemp products through its existing channel partners. LiveWell entered into a strategic agreement with Canopy Rivers and Canopy Growth in April 2018.
• PharmHouse (private) is a joint venture between Canopy Rivers and the principals and operators of leading North American greenhouse produce companies. PharmHouse has arranged to acquire a newly built 1.3-million-square-foot greenhouse located in Leamington, Ontario.
• Radicle Cannabis Inc. (private) is an ACMPR-licensed cannabis company based in Hamilton, Ontario backed by a management team that brings extensive experience in regulated industries, retail distribution, tobacco and pharmaceutical development, as well as Award-winning cannabis horticulturist breeders and medical professionals.
• Solo Growth (TSXV:ALZ) is a new cannabis retail concept that will operate locations under the name “YSS by Solo,” relying on the expertise of a management team comprised of founding shareholders, senior officers and board members of Solo Liquor Stores Ltd., a leading Canadian liquor retailer. Solo Growth was established through a recapitalization of Aldershot Resources Ltd.’s corporate structure that will allow the company to execute a new retail-focused cannabis business strategy.
• Spot Therapeutics Inc. (private) is an applicant that was acquired by Canopy Growth in August 2017 to solidify its Maritimes expansion strategy and less than four weeks later Canopy Growth signed a supply MOU with the New Brunswick government. Canopy Rivers purchased the property and entered into a long-term lease and committed funding agreement with Canopy Growth.
• TerrAscend Corp. (CSE:TER) cultivates high-quality cannabis in an indoor hydroponic facility, backed by a strategic investor boasting a strong background in the pharmaceutical space and an extensive portfolio of specialty pharma assets.
• Vert Mirabel (private) is a joint venture that was established in December 2017 between Canopy Rivers, Canopy Growth, and Les Serres Stephane Bertrand. Bertrand is a large-scale greenhouse operator located in Mirabel, Quebec, and the largest grower of pink tomatoes in the country. With guidance and assistance from Canopy Growth, the greenhouse has been upgraded and retrofitted for cannabis production and was licensed by Health Canada in May 2018.

As the company’s portfolio continues to develop, each constituent benefits from opportunities to collaborate with Canopy Growth and among themselves. Canopy Rivers believes this formula results in an ideal environment for innovation, synergy and value creation for Canopy Rivers, Canopy Growth and across the entire Rivers ecosystem.

Canopy Rivers is led by an experienced team of qualified financial and technical professionals with deep industry experience and relationship networks. The company’s acting CEO and chairman is Bruce Linton, CEO of Canopy Growth and founder of Tweed Marijuana.

Canopy Rivers Inc. (TSX.V: RIV), closed the day's trading session at $4.53, off by 0.44%, on 462,176 volume with 1,317 trades. The average volume for the last 3 months is 502,204 and the stock's 52-week low/high is $2.40/$11.82.

Recent News

• Canopy Growth subsidiary and Canopy Rivers portfolio company Vert Mirabel now fully licensed by Health Canada
• Canopy Rivers Hosts Analyst and Investor Day on May 28 - Live Webcast Available
• Five of the Most Popular Cannabis Stocks to Watch in 2019

Genprex Inc. (NASDAQ: GNPX)

The QualityStocks Daily Newsletter would like to spotlight Genprex Inc. (NASDAQ: GNPX).

Gene therapy could potentially advance the creation and delivery of effective cancer treatments in the years to come. Various companies are leading the way, and pioneers such as Genprex Inc. (NASDAQ: GNPX) are pushing for the introduction of innovative and targeted therapies that have the potential to help patients with various malignancies.

Genprex Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

Research and Development

Genprex holds a portfolio of 30 issued and two pending patents covering its technologies and targeted molecular therapies. The company’s research and development program is focused on identifying and developing leading-edge gene therapies that can be used alone or in combination with other therapies for treatment of cancer.

Genprex’s initial product candidate is Oncoprex™, an immunogene therapy for the treatment of non-small cell lung cancer (NSCLC). Oncoprex works by interrupting cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis (or programmed cell death) in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

Preclinical research is being conducted with the goal of developing Oncoprex to be administered with targeted therapies in other solid tumors, and with immunotherapies in NSCLC and other solid tumors. In addition, Genprex has conducted and plans to continue research into other tumor suppressor genes associated with chromosome 3p21.3, as well as other potential applications of the company’s immunogene therapy platform.

Clinical Trials

Genprex is currently conducting the second phase of a phase I/II clinical trial at the University of Texas MD Anderson Cancer Center in Houston. The company plans to expand its clinical program by adding a new clinical study evaluating Oncoprex™ in combination with a checkpoint inhibitor for treatment of Stage IV or recurrent NSCLC. In research presented at the 2017 Annual Meeting of the American Association of Cancer Research in Washington, D.C., Genprex’s collaborators showed that TUSC2 in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in lung cancer than either agent alone. The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlating with prolonged survival in mice.

TUSC2 (Tumor Suppressor Candidate 2) is a tumor suppressor gene that is absent or deficient in cancer cells of many different cancer types.

The Market

Genprex technologies seek to bridge a critical gap by combining with targeted therapies and immunotherapies to provide treatments to large patient populations who would otherwise not be candidates for those therapies or who have become resistant to them. Genprex technologies are being developed to overcome genomic limitations which are inherent in targeted therapies and immunotherapies in order to provide new treatment solutions to large cancer populations, such as those with lung cancer.

Each year, more people die of lung cancer than of colon, breast and prostate cancers combined. NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancers, according to the American Cancer Society (“ACS”). Despite radical advances in drug development and novel therapeutic standards, survival for late stage lung cancer has not improved significantly in the past 25 years.

Senior Management

Chairman and Chief Executive Officer J. Rodney Varner, JD, is a co-founder of Genprex and has served in these roles since August 2012. He has more than 35 years of legal experience with large and small law firms and as outside general counsel of a Nasdaq-listed company. Varner has served as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation. He is a member of the State Bar of Texas and has been admitted to practice before the U.S. Court of Appeals for the Fifth Court and the U.S. Tax Court.

Julien L. Pham, M.D., MPH, is president and chief operating officer of Genprex. In March 2013, Dr. Pham co-founded RubiconMD, a healthcare IT company that connects primary care providers to specialists for additional guidance and opinions on medical cases and served as its chief medical officer. He has served on the faculty at Harvard Medical School’s Brigham and Women’s Hospital and is a board-certified internal medicine doctor and nephrologist.

Ryan M. Confer, MS, has served as Genprex chief financial officer since September 2016. Confer has more than 10 years of executive experience in planning, launching, developing, and growing emerging technology companies and has served in the chief operating and chief financial roles for non-profit and for-profit entities since 2008. Confer has also served as an international business development consultant for the University of Texas at Austin’s IC2 Institute, where he focused on evaluating the commercialization potential of nascent technologies in domestic and international markets applicable to technology incubator programs associated with the University. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.

Jan Stevens, RN, is vice president of Clinical Operations. Stevens has nearly 20 years of comprehensive clinical operations experience in the biopharma industry and a specialization in early-to-late stage oncology companies. Stevens joined the company to help support the various clinical development programs for Oncoprex™.

Genprex Inc. (NASDAQ: GNPX), closed the day's trading session at $1.60, off by 0.16%, on 23,271 volume with 64 trades. The average volume for the last 3 months is 50,244 and the stock's 52-week low/high is $0.95/$12.24.

Recent News

• Genprex Inc. (NASDAQ: GNPX) Pioneering an Innovative Cancer Therapy, Preclinical Data Shows Positive Results
• NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Details Plans to Present at Sachs 5th Annual Immuno-Oncology BD&L and Investment Forum
• NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Taking Unique Gene Therapy Approach to Cancer Treatment

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF)

The QualityStocks Daily Newsletter would like to spotlight Wildflower Brands Inc. (WLDFF).

Wildflower Brands Inc. (CSE: SUN, OTC: WLDFF) (the “Company” or “Wildflower”) announces that it has executed a share purchase agreement (the “Definitive Agreement”) with City Cannabis Corp. (“City Cannabis”) to acquire all of the issued and outstanding shares of City Cannabis (the “Acquisition”). Also today, NetworkNewsWire released a report on the company detailing how WLDFF was recently featured in an article on Miss Grass. Madison Margolin, the author of the article, ‘HIGH CITY GUIDE: Los Angeles,’ mentions one of LA’s monthly pop-up events, Zen & Kush, and recommends Wildflower's CBD vaporizer to enjoy at the booze-free event. The vaporizer’s blend of lavender and peppermint leaves customers with an icy cool relief from aches and pains. It is available for purchase on the Miss Grass website for $60.00 (http://nnw.fm/8tpGX). To view the full article, visit: http://nnw.fm/Btm71.

Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) is a public cannabis company developing and designing brands that focus on plant-based wellness and health products. Wildflower markets its full-spectrum CBD products to retailers in the health and wellness space throughout the United States and in legal cannabis markets in accordance with regulations marketing its THC and CBD products.

Headquartered in Vancouver, British Columbia, Canada, Wildflower employs a unique and holistic business model that encompasses research and development, manufacturing, distribution, marketing and retail. First launched in 2012 as a private company with a cannabis-focused brand, Wildflower went public in 2014 and has since reached numerous significant milestones in its drive to create brands that work in synergy toward becoming a global wellness brand leader.

Gathered within the growing family of Wildflower brands are the following entities:

• Wildflower Wellness is known for its reputable brand, uncompromising quality and mission to connect people with the healing power of plants. Wildflower Wellness offers CBD vaporizers, capsules, tinctures, soaps and topicals that are backed by a 100 percent satisfaction guarantee. Wildflower Wellness offers a full lineup of full spectrum CBD extract infused products made in the U.S. in Wildflower’s GMP facilities which are always third-party lab tested for quality assurance and accurate labeling.
• King Extracts is a California-based company focused on cannabis technology and delivery systems. The King Recharge is a discreet, 97mm small, rechargeable vaporizer with a sleek pocket-sized charging and storage case. King concentrates are clean and sophisticated blends made from CO2 extractions that are fractionally distilled for clarity and purity with proprietary terpenes blended in to deliver a robust, full-flavor profile. King products are available at 26 select, regulated retail dispensaries in California.
• Exclusive is a dispensary of high-quality cannabis products and accessories serving the city of Los Angeles, California. The company enjoys a close association with select hospital oncology departments and community programs.

Using the slogan “Plants Heal,” Wildflower’s distribution network in the U.S. includes 200+ retailers in Washington state and 20+ retailers in New York City. Wildflower has also partnered with Retail Worx to establish shop-in-shop retail locations in the heart of New York City which pairs nicely with the introduction of Wildflower into existing Bridges General’s stores in New York City and San Francisco. Through this partnership with Retail Worx, Wildflower by Bridges General stores will have exclusive product offerings in addition to the full lineup of existing Wildflower Wellness CBD products. Distribution in other U.S. markets includes 80+ wellness and healthcare practitioners with a total distribution of over 300 stores nationwide.

Wildflower holds 14 California cannabis licenses that cover recreational and medical cannabis cultivation, manufacturing, distribution and retail/delivery in the jurisdictions of California state and the city of Los Angeles. Opportunities to activate these licenses creates the phenomenal potential of driving significant revenues while minimizing risk. Expansion plans into Canada are underway with discussions centered on retail acquisitions and Wildflower launching into over-the-counter market with its CBD product line. Global expansion is a key part of Wildflower’s strategy with initial plans aimed at specific international markets where regulatory hurdles are less restrictive.

In December 2018, Wildflower began on-demand, legal and licensed cannabis delivery services to adult consumers in the Los Angeles area and has hired dozens of full-time delivery drivers to accommodate this unmet need. Wildflower has partnered with leading technology and logistics company Eaze.com to help route deliveries efficiently, manage inventory and comply with California law. Providing legal, licensed delivery services helps to ensure that all adults including those with mobility challenges and limited access to transportation services can purchase high quality, legal cannabis products.

Wildflower’s direct-to-consumer online store sales have shown an organic growth. The Company recently achieved over 300 percent growth in online sales since January 2018 with annualized revenues exceeding $1 million for online sales only, marking the ninth consecutive quarter of increased revenue.

Core Team

William MacLean is the founder and CEO of Wildflower Brands Inc. His involvement in all aspects of the business from product R&D to manufacturing setup has led the Company to its current success. MacLean is a seasoned sales professional with over 20 years of experience in various industries from advertising and marketing to medical sales. While in the advertising and marketing space, his clients included major brands including: Bell, Remax, BC Hydro, and Royal Bank.

CFO Stephen Pearce is a director and officer of a number of public companies in the resource sector. His professional experience as a practicing attorney is primarily in corporate and securities work. Pearce’s academic background includes an honors bachelor’s degree in economics from York University, in which he focused specifically on corporate finance. Pearce obtained a law degree from the University of British Columbia.

Alfred Kee, COO, is a business technology leader with over 15 years of experience in building high performing teams at small startups to large enterprises. With foundations in running large scale business critical technology and user experience product management mindset, Kee excels at guiding teams to deliver business value with agility. His knowledge and experience were honed while working with Electronic Arts, KPMG, CenturyLink, Cisco and Apple, as well as a string of successful startups. Lee brings a global perspective having lived and worked through parts of the U.S., Canada, Europe and Asia.

Creative Director Amy Yamamura is a founding member of Wildflower and has been a driving force behind the Company from the start, creating the Wildflower brand. After receiving a bachelor’s degree in communications from Boston University, Yamamura returned to Tokyo to develop her career in TV as an international business correspondent coordinating collaborative projects between top creators around the world and corporations. Yamamura’s unique experience in working closely with successful Japanese brands like UNIQLO has given her exceptional eyes for branding a company.

Wildflower Brands Inc. (WLDFF), closed the day's trading session at $0.490845, off by 0.76%, on 23,418 volume with 21 trades. The average volume for the last 3 months is 22,937 and the stock's 52-week low/high is $0.009/$1.129.

Recent News

• Wildflower Brands and City Cannabis Sign Definitive Agreement Forming Multi-Country Multi-State-Operator
• NetworkNewsBreaks – Wildflower Brands Inc. (CSE: SUN) (OTCQB: WLDFF) Products Featured in Miss Grass’ LA Guide
• Growing Media Coverage, Celebrity Endorsements Lead to Soaring CBD Popularity

ChineseInvestors.com (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com (CIIX).

ChineseInvestors.com, Inc. (OTCQB: CIIX), an established financial news and investment portal for the global Chinese-speaking community, today announced that it will be presenting at the 9th Annual LD Micro Invitational, to be held June 4–5, 2019, at the Luxe Sunset in Bel-Air, California.

Founded in 1999, ChineseInvestors.com (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world’s first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer’s disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX’s cannabis-focused “Yelp”-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide.

ChineseInvestors.com (CIIX), closed the day's trading session at $0.43, off by 2.69%, on 17,854 volume with 17 trades. The average volume for the last 3 months is 59,754 and the stock's 52-week low/high is $0.365/$1.25.

Recent News

• ChineseInvestors.com, Inc., to Present at the 9th Annual LD Micro Invitational
• NetworkNewsBreaks – ChineseInvestors.com Inc. (CIIX) Subsidiary Becomes First Chinese Company to Sell CBD Products in the US
• ChineseInvestors.com Inc. (CIIX) Offers Cryptocurrency Education Products, Services to Global Chinese-Speaking Subscribers

Sharing Services Global Corporation (SHRG)

The QualityStocks Daily Newsletter would like to spotlight Sharing Services Global Corporation (SHRG).

Sharing Services Global Corporation (OTCQB: SHRG) is utilizing its Blue Ocean Strategy in the direct-selling industry as it prepares to follow up on success in the United States with entry into Canada. The company plans to build on its recent success through its Elepreneur subsidiary and an expanded focus on additional international markets.

Sharing Services Global Corporation (SHRG), headquartered in Plano, Texas, is a diversified holdings company focused on reshaping how entrepreneurs succeed today. Sharing Services Inc. owns, operates or controls an interest in a variety of companies specializing in the direct selling industry that either sell products to the consumer directly through independent representatives or offer services that range from health and wellness, energy, technology, insurance services, training, media and travel benefits. SHRG has created the “Blue Ocean Strategy,” which melds three keys together to implement the company’s vision. These keys include elevating home-based entrepreneurs, known as “Elepreneurs,” utilizing the direct selling channel to generate 100 percent organic growth.

Sharing Services Inc. subsidiaries include:

• A growing international network of home-based entrepreneurs, called “Elepreneurs”
• Growing selection of health and wellness products dedicated to elevating the well-being of all people
• Insurance from auto, home and life to health benefit discounts and health insurance that help families elevate their options
• Wholesale travel and payment programs with travel concierges that empower more families to go on vacation
• Live seminars and training events – from Vacationars™ to EduTainment – that elevate the skills and knowledge of entrepreneurs around the world
• Unique compensation and reward programs crafted to help entrepreneurs elevate their health, wealth and happiness

Sharing Services recently expanded its corporate footprint by moving to a 10,000 square foot facility in Plano, Texas, that offers room to expand as the company grows and its subsidiaries flourish. The larger corporate locale provides space for a growing customer service department, product fulfillment, opportunity and training rooms, as well as a video production suite.

“The opportunity to expand to the rest of this new building over the course of the next six to 12 months ensures we won’t have to move again anytime soon,” Sharing Services Inc. Chairman Robert Oblon said. “We are on track for very significant growth here in the U.S., as well as upcoming international expansion, so this move is in preparation for what’s in front of us.”

The company recently signed a joint venture agreement with Health Wealth & Happiness Limited (“HWH”) to expand its “Elepreneurs” brand and market its products throughout Asia. The newly formed company will be named “Elepreneurs Asia Limited” and will have marketing and sales rights to China, Hong Kong, Macau, South Korea, Japan, Taiwan, Cambodia, Indonesia, Laos, Malaysia, the Philippines, Singapore, Thailand, Vietnam and Papua, New Guinea. A soft launch of the Elepreneur program is scheduled sometime later in 2018 with HWH CEP Fai Chan and his team leading the effort. Formed in Hong Kong, Health Wealth & Happiness Limited is dedicated to working with visionary partners like Sharing Services Inc. to deliver the best products and services to improve the well-being of consumers.

Nearly 1,000 people attended Sharing Services Global Corporation ’s first “Elepreneur Happiness Convention,” held March 2-3, 2018, in Dallas, Texas. Attendees arrived from several countries including the U.S., Canada, Mexico, Singapore and Hong Kong. Keynote speakers included several internationally known motivational leaders – Shawn Achor, Sandra Yancey, John Fleming and Les Brown – who provided exceptional material and inspirational discussion points.

“The enthusiasm of our attendees and the early success that we are experiencing is incredible considering our growth has been 100 percent organic, with almost no marketing from the company,” Oblon said. “I’m speechless by the dedication of our Elepreneur leaders and their entire teams, as they share our incredible line of products that have helped so many people.”

Sharing Services and its management team plan to travel the U.S. to hold several mini conferences to expand on the messages presented at its Happiness Convention that focus on helping people become “healthier, happier and wealthier.” Details of the company’s aggressive global expansion initiatives are soon to be announced, Oblon said.

The law firm of Gardere Wynne Sewell LLP has been retained as outside corporate counsel for all general business matters. The Dallas-based law firm will represent Sharing Services Global Corporation , and its subsidiaries as the company utilizes the direct selling channel for a significant component of its overall growth strategy.

John “JT” Thatchwas appointed president and chief executive officer of Sharing Services Global Corporation , at a March 1, 2018, annual shareholder meeting. Thatch has successfully started, owned and operated several sized businesses in various industries. His experience with corporate growth, acquisitions, financing and negotiation in fast-paced and flexible environments will significantly assist Sharing Services Inc. as the company aims to expand and increase revenues.

Sharing Services Global Corporation (SHRG), closed the day's trading session at $0.17, off by 0.06%, on 100 volume with 1 trade. The average volume for the last 3 months is 23,141 and the stock's 52-week low/high is $0.15/$0.3944.

Recent News

• Sharing Services Global Corporation (SHRG) Focuses on Blue Ocean Strategy, Targets Global Markets
• Sharing Services Global Corporation's (SHRG) New Marketing Strategy Targets US Spanish-Speaking Community
• NetworkNewsBreaks – Sharing Services Inc. (SHRG) Applies for NASDAQ Capital Market Uplisting